This study was performed to determine differences in 123I image quality at 5 and 24 h for the
detection of residual thyroid or recurrent disease in patients with differentiated thyroid cancer …

Objective To determine whether a 5-mCi dose of 123I can be used as an effective
radiotracer for assessing the presence of remnant thyroid tissue and for searching for …

Background Follow-up of 131 I whole-body scanning after 131 I ablation is associated with
potential stunning. Previous studies have suggested that, for scanning, 123 I is more …

Objective To determine whether 123 I can be used as a safe and effective alternative tracer
to 131 I for imaging remnant tissue and for searching for metastatic lesions of well …

Objective We assessed the performance of 37 MBq I-123 as a diagnostic imaging agent in
patients with differentiated thyroid cancer using comparisons with their corresponding high …

Objective The purpose of the present study was to evaluate the clinical usefulness of the
delayed post-therapeutic 131 I scan in patients with well-differentiated thyroid cancer by …

We compared the diagnostic sensitivities of 123I and 131I whole-body imaging in
differentiated thyroid cancer. Methods: Twelve thyroidectomized patients (3 previously …

OBJECTIVE Some patients with relapsed differentiated thyroid cancer may show rising
thyroglobulin (Tg) levels despite a lack of 131I uptake on routine whole body imaging. A …

It is recognized that diagnostic doses of (131) I larger than 3 mCi will cause some cell injury
to the tissue in which it concentrates and reduce subsequent uptake of (131) I administered …

Background 123 I has been promoted for diagnostic imaging as a means of avoiding
'stunning'. It has also been suggested that the more favourable physical characteristics and …